Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Antibody-mediated rejection despite inhibition of terminal complement.

Bentall A, Tyan DB, Sequeira F, Everly MJ, Gandhi MJ, Cornell LD, Li H, Henderson NA, Raghavaiah S, Winters JL, Dean PG, Stegall MD.

Transpl Int. 2014 Dec;27(12):1235-43. doi: 10.1111/tri.12396. Epub 2014 Aug 20.

2.

Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients.

Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, Cosio FG, Gandhi MJ, Kremers W, Gloor JM.

Am J Transplant. 2011 Nov;11(11):2405-13. doi: 10.1111/j.1600-6143.2011.03757.x. Epub 2011 Sep 22. Erratum in: Am J Transplant. 2013 Jan;13(1):241.

3.

Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts.

Burbach M, Suberbielle C, Brochériou I, Ridel C, Mesnard L, Dahan K, Rondeau E, Hertig A.

Transplantation. 2014 Nov 27;98(10):1056-9. doi: 10.1097/TP.0000000000000184.

PMID:
24839895
4.

Rejection despite C5 blockade: a distinct role of IgM?

Böhmig GA, Eskandary F.

Transpl Int. 2014 Dec;27(12):1233-4. doi: 10.1111/tri.12407. No abstract available.

5.

Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation.

Malheiro J, Tafulo S, Dias L, Martins S, Fonseca I, Beirão I, Castro-Henriques A, Cabrita A.

Transpl Int. 2017 Apr;30(4):347-359. doi: 10.1111/tri.12873. Epub 2016 Nov 2.

6.

Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?

Crespo M, Torio A, Mas V, Redondo D, Pérez-Sáez MJ, Mir M, Faura A, Guerra R, Montes-Ares O, Checa MD, Pascual J.

Transpl Immunol. 2013 Dec;29(1-4):28-33. doi: 10.1016/j.trim.2013.07.002. Epub 2013 Jul 29.

PMID:
23907088
7.

A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients.

Vo AA, Zeevi A, Choi J, Cisneros K, Toyoda M, Kahwaji J, Peng A, Villicana R, Puliyanda D, Reinsmoen N, Haas M, Jordan SC.

Transplantation. 2015 Feb;99(2):299-308. doi: 10.1097/TP.0000000000000592.

PMID:
25606785
8.

C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection.

Yell M, Muth BL, Kaufman DB, Djamali A, Ellis TM.

Transplantation. 2015 Jun;99(6):1151-5. doi: 10.1097/TP.0000000000000699.

PMID:
25839705
9.

Complement inhibition as potential new therapy for antibody-mediated rejection.

Eskandary F, Wahrmann M, Mühlbacher J, Böhmig GA.

Transpl Int. 2016 Apr;29(4):392-402. doi: 10.1111/tri.12706. Epub 2015 Nov 10. Review.

10.

Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.

Wu P, Jin J, Everly MJ, Lin C, Terasaki PI, Chen J.

Clin Biochem. 2013 Oct;46(15):1389-93. doi: 10.1016/j.clinbiochem.2013.05.053. Epub 2013 May 29.

PMID:
23726814
11.

The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes.

Freitas MC, Rebellato LM, Ozawa M, Nguyen A, Sasaki N, Everly M, Briley KP, Haisch CE, Bolin P, Parker K, Kendrick WT, Kendrick SA, Harland RC, Terasaki PI.

Transplantation. 2013 May 15;95(9):1113-9. doi: 10.1097/TP.0b013e3182888db6.

PMID:
23514959
12.

Serum flow cytometric C1q binding antibody analysis of renal recipients with low levels of sensitization.

Ata P, Canbakan M, Kara M, Özel L, Ünal E, Titiz Mİ.

Transplant Proc. 2012 Jul-Aug;44(6):1652-5. doi: 10.1016/j.transproceed.2012.05.032.

PMID:
22841237
13.

Impact of IgM and IgG3 anti-HLA alloantibodies in primary renal allograft recipients.

Everly MJ, Rebellato LM, Haisch CE, Briley KP, Bolin P, Kendrick WT, Kendrick SA, Morgan C, Maldonado AQ, Harland RC, Terasaki PI.

Transplantation. 2014 Mar 15;97(5):494-501. doi: 10.1097/01.TP.0000441362.11232.48.

PMID:
24487396
14.

The role of complement-fixing donor-specific antibodies identified by a C1q assay after heart transplantation.

Farrero Torres M, Pando MJ, Luo C, Luikart H, Valantine H, Khush K.

Clin Transplant. 2017 Nov;31(11). doi: 10.1111/ctr.13121. Epub 2017 Oct 15.

PMID:
28940521
15.

Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation.

O'Leary JG, Kaneku H, Banuelos N, Jennings LW, Klintmalm GB, Terasaki PI.

Am J Transplant. 2015 Apr;15(4):1003-13. doi: 10.1111/ajt.13153. Epub 2015 Mar 13.

16.

Renal Transplant Patients Biopsied for Cause and Tested for C4d, DSA, and IgG Subclasses and C1q: Which Humoral Markers Improve Diagnosis and Outcomes?

Cicciarelli JC, Lemp NA, Chang Y, Koss M, Hacke K, Kasahara N, Burns KM, Min DI, Naraghi R, Shah T.

J Immunol Res. 2017;2017:1652931. doi: 10.1155/2017/1652931. Epub 2017 Jan 15.

17.

Eculizumab to treat antibody-mediated rejection in a 7-year-old kidney transplant recipient.

Chehade H, Rotman S, Matter M, Girardin E, Aubert V, Pascual M.

Pediatrics. 2015 Feb;135(2):e551-5. doi: 10.1542/peds.2014-2275.

18.

Role of Pretransplant Complement-fixing Donor-specific Antibodies Identified by C1q Assay in Kidney Transplantation.

Thammanichanond D, Wiwattanathum P, Mongkolsuk T, Kantachuvesiri S, Worawichawong S, Vallipakorn SA, Kitpoka P.

Transplant Proc. 2016 Apr;48(3):756-60. doi: 10.1016/j.transproceed.2015.12.116.

PMID:
27234729
19.
20.

Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads.

Chen G, Sequeira F, Tyan DB.

Hum Immunol. 2011 Oct;72(10):849-58. doi: 10.1016/j.humimm.2011.07.001. Epub 2011 Jul 18.

PMID:
21791230

Supplemental Content

Support Center